A New Name for PCOS: The EGOI-PCOS Perspective

May 13, 2026

The publication in The Lancet of the article “Polyendocrine Metabolic Ovarian Syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process” marks a historic moment in the evolution of the syndrome traditionally known as PCOS.

For the first time, the international scientific community officially recognizes something that many researchers and clinicians have been discussing for years: this condition is not simply ovarian, nor exclusively gynecological. It is a systemic endocrine-metabolic disorder in which insulin dysfunction and metabolic alterations play a central biological role.

As EGOI-PCOS, we warmly welcome this important step.

For years, our group has been among the earliest scientific voices advocating for a rethinking of the syndrome’s nomenclature and pathophysiological interpretation. Through multiple publications and international discussions, we consistently emphasized the limitations of the term Polycystic Ovary Syndrome, which risks reducing a highly complex systemic condition to a morphological ovarian finding.

The new term Polyendocrine Metabolic Ovarian Syndrome (PMOS) represents a significant shift forward because it finally incorporates the endocrine and metabolic dimensions of the syndrome into its very name. This is not merely a semantic change.

It reflects a profound transformation in how the syndrome is understood, diagnosed, and managed clinically.

For years, EGOI-PCOS has supported the idea that hyperinsulinemia, insulin resistance, chronic low-grade inflammation, and metabolic dysfunction are not secondary features of the syndrome, but among its main biological drivers. This perspective led us to propose the term Endocrine Metabolic Syndrome (EMS) as a more coherent definition of the condition’s systemic nature.

Today’s publication represents an important scientific recognition of the direction that EGOI-PCOS has supported through several scientific contributions, including:

This clearly confirms that the scientific community is progressively moving toward a broader endocrine-metabolic interpretation of the syndrome.

At the same time, we also believe that the discussion is not fully concluded.

While PMOS undoubtedly represents an important advancement, some aspects of the new terminology may still deserve critical reflection. In particular, the persistence of the term “ovarian” may continue to partially limit the perception of the syndrome to reproductive and gynecological aspects, despite its much broader systemic implications. Likewise, the prefix “poly” may still generate potential ambiguity.

Scientific progress, however, has never been built on passive consensus alone. It evolves through debate, critical thinking, and the courage to challenge outdated paradigms.

What is still largely theoretical within many scientific frameworks has already become clinical reality within the EGOI-PCOS network.

Over recent years, EGOI-PCOS Clinics have rapidly expanded internationally, responding to a real and long-overdue clinical need from patients seeking an integrated endocrine-metabolic approach to the syndrome.

In Italy, six specialized centers are already active or in development, including San Camillo Hospital in Rome, the first public referral center specifically dedicated to these women. Internationally, the network continues to grow through collaborations in Poland, Russia, Georgia, and Brazil.

This clinical development reflects a precise vision: women affected by this syndrome should not be managed only through the lens of fertility or ovarian morphology, but through a multidisciplinary, long-term approach focused on metabolic health, cardiovascular prevention, body composition, insulin dysfunction, and quality of life.

Today’s change is therefore far more than a new acronym.

It is the recognition of a new scientific identity.

And perhaps, only the beginning of an even deeper transformation in the way this syndrome will be understood in the years to come.